Moxifloxacin-induced mental status change

Sertaç Güler; Dilber Kocaşaban

doi:10.5937/afmnai40-36485

Case report

Published: 01.12.2022.

<< Prev | Next >>

PDF

https://doi.org/10.5937/afmnai40-36485

Moxifloxacin-induced mental status change

Abstract

Moxifloxacin is an antibiotic used orally or parenterally in the emergency department (ED) for the treatment of various infections, especially acute exacerbation of chronic bronchitis and community-acquired pneumonia. The side effects of the drug are mainly on the gastrointestinal system, while the central nervous system side effects are rare. Herein, we present an elderly patient who had altered mental status associated with the use of moxifloxacin. Upon discontinuation of the drug, the patient quickly returned to baseline neurologic status. In the evaluation of altered mental status in elderly patients in the ED, much of the effort should be spent primarily on ruling out more complex diagnoses. However, this approach requires more invasive and advanced testing. Considering drug side effects among these more complicated diagnoses may increase noninvasive and radiation-free options for the patient and physician.

Keywords:

adverse drug reaction,

central nervous system,

emergency medicine,

mental orientation,

moxifloxacin (MeSH Database)

References

Douros A, Grabowski K, Stahlmann R. Safety issues and drug–drug interactions with commonly used quinolones. Expert Opinion on Drug Metabolism & Toxicology. 2015;11(1):25–39.

Mazhar F, Akram S, Haider N. Moxifloxacin-induced acute psychosis: A case report with literature review. Journal of Research in Pharmacy Practice. 2016;5(4):294.

Fish DN. Fluoroquinolone Adverse Effects and Drug Interactions. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2001;21(10P2).

Stahlmann R, Lode H. Safety Considerations of Fluoroquinolones in the Elderly. Drugs & Aging. 2010;27(3):193–209.

Carbon C. Comparison of Side Effects of Levofloxacin versus Other Fluoroquinolones. Chemotherapy. 2001;47(Suppl. 3):9–14.

Elbe DH, Chang SW. Moxifloxacin—Warfarin Interaction: A Series of Five Case Reports. Annals of Pharmacotherapy. 2005;39(2):361–4.

Tasleem H, Viswanathan R. Moxifloxacin-Induced Delirium With Hallucinations. Psychosomatics. 2011;52(5):472–4.

Pedrós A, Tomás A, Emilio Gómez J, Ángel Navarro L. Levofloxacino y síndrome confusional agudo. Medicina Clínica. 2002;119(1):38–9.

Chui CSL, Chan EW, Wong AYS, Root A, Douglas IJ, Wong ICK. Association between oral fluoroquinolones and seizures. Neurology. 2016;86(18):1708–15.

10.

Haiping L, Ziqiang J, Qina Z, Yuhua D. Adverse reactions of fluoroquinolones to central nervous system and rational drug use in nursing care. Pak J Pharm Sci. 2019;32:427–32.

11.

Etminan M, Brophy JM, Samii A. Oral fluoroquinolone use and risk of peripheral neuropathy. Neurology. 2014;83(14):1261–3.

12.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics. 1981;30(2):239–45.

13.

Freeman MZ, Cannizzaro DN, Naughton LF, Bove C. Fluoroquinolones-Associated Disability: It Is Not All in Your Head. NeuroSci. 2(3):235–53.